Josephine Harrington, MD, is an advanced heart failure and transplant fellow at Duke University.

Bumetanide Nasal Spray and the Future of Edema With Josephine Harrington, MD, and Nihar Desai, MD

 approved bumetanide nasal spray for the treatment of edema associated with congestive 

, liver disease, and kidney disease. Under the name ENBUMYST, the spray is the first and only intranasal loop diuretic approved in the US offering a self-administered alternative between oral and intravenous diuretics.

Loop diuretics are the standard first-line treatment for congestion, and are used to control patients’ volume status in HF. Most patients admitted to the hospital are given intravenous loop diuretics, regardless of perfusion status or other factors. However, blunted use of loop diuretics leads to blunted diuretic response in acute decompensated HF, which is related to functional and structural tubular remodeling. Bumetanide nasal spray was developed in part to circumvent the gastrointestinal absorption issues.

In addition to revitalizing diuretic therapy for patients with HF, bumetanide has the capacity to overhaul key factors of the HF treatment landscape and open the way to address the unmet need of edema. 

 spoke with Josephine Harrington, MD, an advanced heart failure and transplant fellow at Duke University, and Nihar Desai, MD, MPH, an associate professor of medicine and vice chief of the section of cardiovascular medicine at Yale University, to discuss the implications of this groundbreaking approval.

“Too many of our patients become resistant, or traditional oral diuretics are ineffective, and so we need other ways to optimize their volume status,” Desai told 

. “I was quite excited to see the data for the intranasal bumetanide, and I think that it does have a very important role to play for some of our patients.”

Harrington expressed her curiosity on how bumetanide will fit into the overall HF treatment cascade. She highlighted the lack of intranasal medications in cardiology prior to this approval, leaving many clinicians with limited experience prescribing similar drugs. She noted this as a potential gap in knowledge, possibly limiting the clinical uptake of bumetanide nasal spray.

“I think there are some opportunities to understand how this could fit into a patient’s armamentarium for symptom relief,” Harrington said. “But candidly, I think a lot of us need a lot more experience with this. Most of us don’t prescribe intranasal drugs as cardiologists regularly.”

Edema and fluid overload are still the leading causes of hospitalization for patients with congestive HF – recent estimates suggest 6.7 million Americans live with heart failure, and fluid overload directly causes >1 million hospitalizations annually. The bumetanide nasal spray is a step towards alleviating this unmet need and could potentially provide a path towards approval for future diuretic drugs to follow.

“Getting back to the very fundamental aspects of heart failure management, diuretics have and always will play a very important role in that,” Desai told

. “Having some of these novel mechanisms and routes of administration offers a really important adjunctive part of our medical intervention for our patients.”

“Edema is a condition that bothers patients quite a great deal, and they’re always interested in ways to manage it that don’t affect their quality of life,” Harrington said. “I think having another arrow in your quiver to do that is always going to be a good thing. And exactly what the role is going to be compared to oral diuretics, I think still remains to be seen.”

Corstasis Therapeutics, Inc. Corstasis Therapeutics Announces FDA Approval of ENBUMYST (bumetanide nasal spray) for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease, and Kidney Disease. Business Wire. September 15, 2025. Accessed September 17, 2025. 

https://www.businesswire.com/news/home/20250915243998/en/Corstasis-Therapeutics-Announces-FDA-Approval-of-ENBUMYST-bumetanide-nasal-spray-for-the-Treatment-of-Edema-Associated-with-Congestive-Heart-Failure-Liver-Disease-and-Kidney-Disease

Biegus J, Ponikowska B, Canonico ME, Damman K, Palazzuoli A, Ambrosy AP. Bumetanide nasal spray: a novel approach to enhancing diuretic response and advancing ambulatory heart failure care?. Heart Fail Rev. 2025;30(5):1123-1126. 

Videos

Harrington and Desai weigh in with their thoughts on the bumetanide approval and how we can continue to battle edema in heart failure.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Chief of Pediatric Rheumatology at Hackensack University Medical Center, and Professor of Pediatrics at the Hackensack Meridian School of Medicine.

Advancing Research and Care in Juvenile Arthritis, With Yukiko Kimura, MD

Management for juvenile idiopathic arthritis (JIA), the most common rheumatologic disease in children, has undergone a dramatic shift in outcomes over the past 2 decades. Once a condition that frequently left children with visible disability, limited mobility, and lifelong complications, JIA is now often managed successfully with targeted therapies that prevent severe damage and help children live active, healthy lives. This progress is largely attributed to the advent of biologics, beginning with TNF inhibitors and now extending to a wide array of therapies with distinct mechanisms of action, including IL-6 inhibitors, T-cell co-stimulation blockers, and JAK inhibitors.

 The expansion of treatment options has not only improved quality of life but has also transformed how clinicians approach disease control in pediatric populations.

Alongside therapeutic breakthroughs, international collaboration has become a driving force in JIA research. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) in North America and the Pediatric Rheumatology European Society (PReS) have joined efforts to launch some of the first global investigator-initiated studies in this space. One such initiative, the SMART-JIA trial, seeks to address a longstanding clinical question: how to optimize treatment strategies for patients who do not respond to first-line biologics.

 With multiple biologic and targeted options available, determining which pathway to pursue after treatment failure remains a challenge for clinicians. Another critical area of investigation focuses on when and how it may be safe to taper or discontinue therapy, an issue of great importance for patients and families navigating long-term treatment.

 spoke with Yukiko Kimura, MD, Chief of Pediatric Rheumatology at Hackensack University Medical Center, and Professor of Pediatrics at the Hackensack Meridian School of Medicine, to learn more about her experience with the evolving treatment landscape. Kimura, who is also cochair of the CARRA Registry and Research Oversight Committee (RROC), also highlighted the importance of ongoing research to address these pressing questions in JIA care.

“The kids that get diagnosed [with pediatric arthritis] can really benefit from knowledge of specialists in this area who know how to use [biologics] and can treat them the way that they should be,” Kimura said.

Shishov M, Weiss PF, Levy DM, et al. 25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges. 

. 2025;77(5):573-583. doi:10.1002/acr.25482

Trial of Sequential Medications After TNF Failure (SMART) and Precision Treatment Decisions in Juvenile Idiopathic Arthritis. CARRA. 

https://carragroup.org/grant/trial-of-sequential-medications-after-tnf-failure-smart-and-precision-treatment-decisions-in-juvenile-idiopathic-arthritis/

Kimura highlighted some of her ongoing research tackling high priority questions in JIA.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A recent study suggests that confounding may explain the increased risks of 

associated with prenatal prescribed opioid analgesic (POA) exposure.

Many obstetrician-gynecologists prescribe opioid analgesics to help manage their patients’ pregnancy pain. However, research has suggested a potential link between prenatal POA exposure and neurodevelopmental disorders.

It was not known if the association between prenatal POA exposure and neurodevelopmental disorders in children is causal or driven by confounding. In this retrospective study, investigators analyzed how the dose and duration of POA use during pregnancy were associated with autism and ADHD risk in children.

“We wanted to conduct this study to help provide more information for pregnant individuals and their physicians who are trying to make complex decisions about how to best manage pain during pregnancy,” said lead investigator Emma N. Clearly, BA, from Indiana University Bloomington, and colleagues, in a statement.

 “While this study is not able to rule out small increased risks with high amounts of exposure, the results suggest that there is not a causal effect of prescribed opioid analgesics on risk for two common neurodevelopmental disorders, providing more data to support decision-making.”

Using national register data from Sweden, this study examined a population-based cohort, with nearly half female (48.6%).

 The ASD cohort included 1,267,978 children born between July 1, 2007, and December 31, 2018, with a follow-up through 2021. Since ADHD is typically diagnosed later, investigators applied a shorter eligibility window, including 918,771 children born through December 31, 2015.

The team used test-mining algorithms to calculate cumulative dose and duration of POA exposure during pregnancy from filled prescriptions and to identify those prescribed on an “as needed” basis.

 Outcomes included inpatient or outpatient clinical diagnoses of ASD and ADHD or dispensed ADHD medications.

To address unmeasured confounding, the analysis incorporated several comparison groups: children whose birthing parent had a diagnosed painful condition but did not receive POAs, children whose birthing parent received POAs in the year prior to but not during pregnancy, and unexposed siblings.

Among the 1,267,978 children, 4.4% were exposed to POAs when in their mother’s womb. At 10 years old, the cumulative incidence of ASD was 3.6% and 2.9% among children exposed to high and low POA doses, respectively, compared with 2% among children unexposed to POAs.

Unadjusted models (hazard ratio [HR], 1.74;

1.63–1.87) and models adjusted for measured covariates (HR, 1.34

 95% CI, 1.24–1.44) showed that the cumulative maximum POA dose was associated with an increased risk of ASD. However, these associations were weak or nonexistent in alternative study designs, particularly when compared with children whose birthing parent had received POAs before, but not during, pregnancy (HR, 1.10; 95% CI, 1.00 – 1.21). The sibling comparison analysis showed no associations between ASD and POA exposure (HR, 0.99; 95% CI, 0.81 – 1.21).

Investigators noted that they did not assess the impact of extremely high doses and long durations of opioids due to limited data in the Swedish cohort.

“We are excited to share our findings because we believe that they have important clinical implications,” said investigator Ayesha C. Sujan, PhD, from Stanford University School of Medicine, in the statement.

 “Our findings suggest that the observed associations between prenatal exposure to opioid analgesics and two major neurodevelopmental disorders—autism and ADHD—are largely driven by factors leading up to opioid analgesic use rather than the opioid exposure itself. Our results, therefore, elucidate the critical need to provide pregnant individuals experiencing pain with psychosocial support and evidence-based pain management tools. These can include both pharmaceutical and non-pharmaceutical approaches.”

Cleary EN, Sujan AC, Rickert ME, et al. Prescribed opioid analgesic use in pregnancy and risk of neurodevelopmental disorders in children: A retrospective study in Sweden. 

. 2025;22(9):e1004721. Published 2025 Sep 16. doi:10.1371/journal.pmed.1004721

Prescribed opioid pain medications during pregnancy likely aren’t associated with increased risk of autism, ADHD. EurekAlert! Published September 16, 2025. Accessed September 17, 2025. https://www.eurekalert.org/news-releases/1097557

Articles

A recent study explored the potential link between prenatal prescribed opioid analgesic (POA) exposure and neurodevelopmental disorders such as autism spectrum disorder (ASD) and ADHD. The research, using Swedish national register data, analyzed the dose and duration of POA exposure during pregnancy. Findings suggest that the observed associations are likely due to confounding factors rather than a causal relationship. The study emphasizes the importance of providing pregnant individuals with psychosocial support and evidence-based pain management strategies, both pharmaceutical and non-pharmaceutical, to manage pregnancy-related pain effectively.

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.


Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

ADHD

ADHD condition center page is a comprehensive resource for clinical news and insights on ADHD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for ADHD.

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

 may be sustained or improved across disease measures through to Week 16, according to recent data.

These late-breaking findings were presented in a session at the 

European Academy of Dermatology and Venereology (EADV)

, with trial investigators including Kim A. Papp, MD, PhD, FRCPC, the founder and president of Probity Medical Research. Papp and colleagues had evaluated both the efficacy and the safety of izokibep, a novel interleukin (IL)-17A inhibitor, for patients living with moderate to severe HS.

The investigators highlighted HS as a chronic, systemic 

 marked by painful nodules, abscesses, and draining tunnels. Dysregulation of interleukin-17A (IL-17A) is said to be a key driver of the condition’s pathology. Izokibep, a novel molecule, has been engineered to selectively block IL-17A, given that it demonstrates exceptionally high binding affinity (Kd: 0.3 pM), has a small molecular size of 18.6 kDa—approximately 1-tenth that of a monoclonal antibody—and contains an albumin-binding domain designed to extend plasma half-life and potentially increase delivery to inflamed tissue.

The 16-week results from a randomized, double-blind, placebo-controlled, multicentre, phase 3 study were highlighted by Papp and coauthors in these late-breaking findings. The phase 2b/3 trial involved the recruitment of individuals living with moderate to severe HS who had a confirmed diagnosis for at least 6 months and lesions in 2 or more anatomical areas. These areas would include at least 1 Hurley stage II or III area.

Participants in Papp and colleagues' research were required to have a lack of a total abscess and inflammatory nodule (AN) count of 5 or greater. They would also have to report a history of intolerance, inadequate response, or contraindication to oral antibiotics. Previous treatment with IL-17 or IL-17 receptor inhibitors was also not permitted.

Eligible individuals involved as study subjects were randomized to 1 of the following cohorts of the analysis: izokibep 160 mg once weekly (QW), placebo QW with crossover to izokibep 160 mg QW, or izokibep 160 mg QW (continued treatment)
Key efficacy measures that the investigative team assessed at Week 16 and which were sustained through Week 76 included HiSCR50/75/90/100 (attainment of ≥50%, 75%, 90%, or 100% reduction in participants' AN count). Additionally, any shifts in the Dermatology Life Quality Index (DLQI), skin pain improvements of ≥3 points on the Numeric Rating Scale (NRS), reductions in AN count to ≤2, and flare frequency. Safety evaluations included treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), serious adverse events (SAEs), laboratory testing, and vital signs.

Izokibep was generally shown to be well tolerated, with Papp and colleagues concluded that no new safety concerns and no reported cases of candidiasis took place. Subjects being given izokibep experienced early and clinically meaningful improvements over placebo that were sustained through Week 16 and beyond.

More than one-third of treated subjects attained HiSCR75 at Week 16, and over 20% attained HiSCR100, suggesting complete clearance of AN lesions. Improvements were also observed in pain reduction, AN count, and quality of life scores, underscoring izokibep’s potential as a targeted therapy for moderate to severe HS.

Papp K, Bechara F, Kimball A, et al. Efficacy and safety of izokibep, a novel interleukin-17A inhibitor, in moderate to severe hidradenitis suppurativa: Week 16 results from a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Sept 17-20, 2025.

Izokibep, a novel IL-17A inhibitor, shows promise in treating moderate to severe hidradenitis suppurativa (HS), with sustained improvements in disease measures through Week 16. The phase 3 study demonstrated significant efficacy, with over one-third of participants achieving HiSCR75 and more than 20% achieving HiSCR100, indicating complete clearance of lesions. Izokibep was well tolerated, with no new safety concerns reported. The study highlights izokibep's potential as a targeted therapy for HS, offering improvements in pain, lesion count, and quality of life for patients.

This study highlights improvements with izokibep for HS, sustained or improved across disease measures through to Week 16.


Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Izokibeb Effective in 16 Weeks Among Patients with Moderate to Severe Hidradenitis Suppurativa

Allysa Saggese, NP, is a nurse practitioner at Weill Cornell.

Collaboration and Innovation in MASH Management, With Allysa Saggese, NP

Metabolic dysfunction–associated steatohepatitis (MASH)

 remains a pressing concern in hepatology, presenting substantial risks of progression to advanced liver disease, cancer, and the need for transplantation.

Communicating this reality effectively to patients is a key step in care. Clear discussions about what fatty liver and fibrosis mean, and why they matter, help patients understand both the risks and the importance of early intervention, as explained by Allysa Saggese, NP, a nurse practitioner at Weill Cornell, at the 

2025 Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) conference

Lifestyle measures continue to be the cornerstone of management, with diet, physical activity, and weight management forming the foundation of care even as pharmacologic options expand. Saggese emphasizes how framing these conversations in approachable ways, using terms like “activity” instead of “exercise” and emphasizing weight management rather than strict weight loss, can help make treatment goals more realistic and patient-centered.

“I talked a lot about the word choices I use and the way I describe the non-pharm bits to my patients, and making sure that's a collaborative relationship that I think comes from sitting down and just paying attention to what they're saying to you and trying to understand what you can do with what they've just told you,” Saggese explained.

On the pharmacologic front, the MASH treatment landscape is evolving, with 2 therapies now approved by the US Food and Drug Administration in the forms of resmetirom and semaglutide. With no strict sequencing guidelines, Saggese says clinicians and patients must work together to choose the therapy that best fits individual needs, preferences, and care plans.

“Some of the biggest gaps [we still see] in MASH care is identifying these patients. I think the base knowledge for other providers who aren't in the specialty can still be improved upon,” she said, explaining the importance of knowing things like how fibrosis can progress even when liver enzymes are normal.

While they may not have the nuanced expertise of hepatology specialists, Saggese says primary care providers can serve as a hub for identifying at-risk patients and directing them to advanced care. Better dissemination of guidelines around who to screen, when, and why could help bridge this gap.

Looking ahead, Saggese expresses excitement about having more therapies to offer patients in the future, explaining how this helps them feel like they have more control over outcomes, side effects, and treatment administration.

“I'm also excited for the better efficacy as we see things come out of trials and improve upon the last trial and improve upon the last drug, just getting better and better,” she said.

Brooks A. Resmetirom (Rezdiffra) Receives Historic FDA Approval for Noncirrhotic NASH. HCPLive. March 14, 2024. Accessed September 10, 2025. 

https://www.hcplive.com/view/resmetirom-rezdiffra-receives-historic-fda-approval-for-noncirrhotic-nash

Brooks A. FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH. HCPLive. August 15, 2025. Accessed September 10, 2025. 

https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash

Saggese explains the importance of effective communication in MASH management and emphasizes the need for more therapies to offer patients.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Compared with non-use, taking semaglutide or tirzepatide was associated with improved rheumatoid arthritis disease activity and cardiovascular risk.

Rheumatoid Arthritis

The HCPLive rheumatoid arthritis page is a comprehensive resource for clinical news and insights on arthritis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for RA, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

GLP-1 RA Use Improves Disease Activity, Cardiovascular Risk in Rheumatoid Arthritis

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Avapritinib shows significant long-term benefits for indolent systemic mastocytosis while maintaining a favorable safety profile.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Avapritinib Demonstrates Durable Improvements in Indolent Systemic Mastocytosis Symptoms, QoL

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The investigational therapy from Innovent Biologics, Inc. displayed significantly greater urate-lowering efficacy versus febuxostat, along with a favorable safety profile.

Gout

On the HCPLive gout page, resources on the topics of medical news and expert insight into gouty arthritis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on gout, and more.

Tigulixostat Proves Superiority to Febuxostat in Patients with Gout and Hyperuricemia

Brogan discusses the various opportunities and challenges that have accompanied recent evolutions in inflammatory bowel disease management.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Access, Affordability, and Innovation in IBD Care, With Jamie Brogan, NP

A study shows children in remission can safely consume peanuts without daily dosing, supporting remission as the primary treatment goal over desensitization.

PRT120 OIT Wins EAACI Prize for Durable Peanut Allergy Remission

Patients with atopic dermatitis treated with camoteskimab saw significant reductions in their mean EASI score at Week 16 compared to placebo.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Camoteskimab Meets Primary Endpoint in Phase 2a Clinical Trial in Atopic Dermatitis

In this analysis, the degree to which each dermatological condition impacts biological aging was highlighted using epigenetic clocks.

HS, Atopic Dermatitis Result in Accelerated Epigenetic Aging Among Patients

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Efzofitimod Fails to Meet Primary End Point in Phase 3 Pulmonary Sarcoidosis Trial

Pankaj Arora, MD, is an associate professor of medicine at the University of Alabama at Birmingham.

Arora discusses the results of Bristol Myers Squibb’s observational study and the implications it has for the study of obstructive HCM and cardiology at large.

Cardiomyopathy

COLLIGO-HCM: Mavacamten (CAMZYOS) Effective in Obstructive HCM With Pankaj Arora, MD

This letter explores off-label dosing adjustments for patients with psoriasis using the IL-17A inhibitors secukinumab and ixekizumab.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Latest News

Bumetanide Nasal Spray and the Future of Edema With Josephine Harrington, MD, and Nihar Desai, MD

Advancing Research and Care in Juvenile Arthritis, With Yukiko Kimura, MD

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk

Izokibeb Effective in 16 Weeks Among Patients with Moderate to Severe Hidradenitis Suppurativa

Collaboration and Innovation in MASH Management, With Allysa Saggese, NP